VivoSeq
Other

Bone Disease

11

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Bone Disease is an emerging landscape with 11 programs across 8 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Pfizer, Alnylam Pharmaceuticals. 3 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

0/100

Mech. Concentration

29/100

Completion Rate

50/100

Attrition Rate

45/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

ApprovedAbbVie logo

AbbVie

1 program

ApprovedAmgen logo

Amgen

3 programs

PreclinicalOtsuka logo

Otsuka

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

10 of 12 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody217%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.

Analysis

Trial Status

11

clinical trials

Completed5 · 45%
Terminated4 · 36%
Withdrawn1 · 9%
Recruiting1 · 9%

Clinical Trials

Trial Activity

11 trials

Identifying Individuals At Risk of Glucocorticoid-Induced Impairment of Bone Disease
Recruiting·OOdense University Hospital·Phase 2·NCT06421597·36 enrolled
Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients
Completed·SStanley Dudrick's Memorial Hospital·Phase 4·NCT02853539·32 enrolled
A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease
Completed·Roche logoRoche·Phase 3·NCT02561039·97 enrolled
Pamidronate, Vitamin D, and Calcium for the Bone Disease of Kidney and Heart Transplantation
Completed·PProvidence Health & Services·N/A·NCT00302627·43 enrolled
A Research Study to Test the Effectiveness of MK0217 in Patients With Paget's Bone Disease (0217-206)(COMPLETED)
Completed·—·Phase 3·NCT00480662·60 enrolled
A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
Completed·Roche logoRoche·Phase 4·NCT02564107·48 enrolled
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
Terminated·Roche logoRoche·Phase 3·NCT00099203·163 enrolled
Bone Disease in Severely Burned Children
Terminated·TThe University of Texas Medical Branch, Galveston·Phase 2/3·NCT00591162·254 enrolled
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
Terminated·WWinthrop University Hospital·Phase 4·NCT01725113·16 enrolled
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
Terminated·Roche logoRoche·Phase 3·NCT00099177·96 enrolled
Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease
Withdrawn·Amgen logoAmgen·Phase 4·NCT02101164

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)